Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 10 Oct 2026

Shilpa Medicare received GMP certification for its Jadcherla unit from AGES, Austria, and SEC approval in India to market OERIS, an extended-release anti-nausea injection.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Shilpa Medicare received GMP certification for its Jadcherla unit from AGES, Austria, and SEC approval in India to market OERIS, an extended-release anti-nausea injection.

cnbctv18.com10 Oct 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.